Background Hidradenitis supppurativa (HS) is a chronic inflammatory disease of the apocrine sweat glands affecting 1-4% of the population. While surgical excision is a
Introduction
Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease of the apocrine sweat glands, characterized by recurrent abscessing inflammation. 1 Patients with HS develop inflammatory nodules, abscesses, and sinus tracts around the apocrine glands. The prevalence of HS is estimated at 1-4% in young adults. [2] [3] [4] [5] Women are affected more commonly than men (with a female to male ratio of 3 : 1), and the disease is more common in African Americans. 6 Surgery has been a mainstay of HS management for some time and is often used for patients with extensive Hurley stage III disease. 7 The best results are achieved with wide local excision, [8] [9] [10] [11] but the disease often recurs, and this has led to a
International Journal of Dermatology 2018, 57, 62-69 ª 2017 The International Society of Dermatology recent interest in the use of targeted biologic therapy in the management of HS. [12] [13] [14] Several recent studies have shown efficacy of tumor necrosis factor-a (TNF-a) inhibitors in mild to moderate HS, 15, 16 and two recent large clinical trials demonstrated efficacy of the humanized monoclonal anti-TNF-a antibody adalimumab 17, 18 leading to orphan drug designation for this indication. Other biologic agents that have shown promise for HS include the IL-12/23 inhibitor ustekinumab. 15, 19, 20 Clinical trials evaluating efficacy of TNF-a inhibitors in HS have not investigated combining biologic therapy as an adjunct to surgical interventions. 17, 21 One of the reasons given for excluding these patients from clinical trials is the potential confounding variable of pain and opioid exposure.
Patients with HS often have significant pain and are prescribed opioid-based medications for symptom control. [22] [23] [24] In chronic wounds 25 and in the postoperative setting, 26 opioid exposure may contribute to delayed healing; however, the impact of opioids on HS disease activity has not been studied in a robust longitudinal analysis.
The purpose of this study was to investigate predictors of HS disease activity scores including surgical interventions, biologic medications, and opioids using a longitudinal and diverse cohort of patients with HS.
Materials and methods

Setting, population, and cohort selection
The Wound Etiology and Healing (WE-HEAL) study (IRB 041408, NCT 01352078) is a longitudinal prospective observational biospecimen and data repository that recruits subjects with chronic wounds and HS. All subjects gave written informed consent for longitudinal collection of their data. This analysis was conducted utilizing data from subjects with confirmed diagnosis of HS. 27 At the time of data lock, there were 568 patients enrolled in the WE-HEAL study, and 68 had confirmed HS.
Data management for WE-HEAL study Data for the WE-HEAL study were abstracted from the electronic health record (EHR) and stored using REDCap. 
Active nodule count
The total number of abscesses and inflammatory nodules (AN)
were assessed at baseline and each visit. AN count is associated with patient-reported quality of life scores and pain level. 30, 31 The probability of achieving AN count reduction in 75% (AN75) is a validated outcome measure used in clinical trials of HS that was assessed in this study.
Modified Hidradenitis Sartorius Score
The modified Hidradenitis Sartorius Score (HSS) is a validated measure of HS activity and was used to assess disease activity at baseline and each visit. 17, 32, 33 
Verbal pain score evaluation
Numerical pain score based on a verbal scale of pain (0-10) was collected at each visit, prior to removing dressings. This is a valid and reproducible score that is in routine clinical use. 34 Baseline pain score was used as a covariate in the static multivariate models and time-to-event analyses. Pain was a time-varying covariate in the fixed-effects mixed models.
Medication exposures
Data on all immunosuppressive and opioid medication were abstracted after each visit. Medication reconciliation is a metric which is audited through the EHR and thus completed at every clinical interaction. Any discrepancies were resolved by adjudication by two investigators (SM and VKS).
Decisions on treatment, including biologic therapy, were driven entirely by clinical care. Biologic agents used in this cohort including anti-TNF-a agents (infliximab dosed IV with typical loading dose of 5 mg/kg at weeks 0, 2, and 6 and 5-10 mg/kg every 6 weeks depending on clinical response or adalimumab dosed at 40 mg subcutaneously weekly) and the IL12/23 inhibitor ustekinumab (dosed based on weight, either 45 mg or 90 mg monthly subcutaneously). The decision to select ustekinumab over a TNF-inhibitor was typically due to presence of one or more autoantibodies, history of drug reaction from TNF-a inhibitor, or coexistent psoriasis which was felt to be more likely to respond to IL-12/23 blockade. As a result of the relatively small sample size, for the purposes of analysis, patients who received any biologic therapy were compared with those who did not.
Daily morphine-equivalent exposure was determined by calculating the quantity of opioid medication ordered by the milligram strength per dosage unit, then multiplying by the published opioid-specific morphine-equivalent conversion factor. 25, [35] [36] [37] Analysis was conducted using the opioidequivalent dose per 24 hours.
Statistical analysis
All analyses were performed using SAS version 9.3 (Cary, NC all available data were used in each analysis.
Analysis models
Analysis was structured around the following study questions with the three HS disease activity measures as dependent variables in the mixed regression models.
1 Does the slope of HS activity differ in patients who ever take biologics vs. never take biologics, and does this persist after adjusting for baseline confounding patient variables, surgery, and opioid exposures? We used a random effects mixed model with the predictors: time, biologic-ever, and the time 9 biologic-ever interaction. The primary focus of this analysis was the time 9 biologic-ever interaction since this investigates whether the slope of HS activity over time varies between treatment groups. To adjust for confounders, we added static covariates known to show significant univariate association with ever receiving biologics, along with surgery and opioid exposures.
2 How strong is the effect of biologic treatment on disease activity, and does this vary with time? In this analysis, we retained any significant static predictors from the prior model and instead of using the static indicator for ever receiving biologics, we used a time-varying binary indicator for biologic treatment, so we could determine the effect of biologics during each time period. In this model, the interaction of biologics 9 time tells us whether the effect of biologics differs across time periods (for example, whether having biologic treatment may be associated with a larger reduction in HS activity from baseline to q3 than from baseline to year 2).
3 Were there differences in HS activity between time periods when patients did vs. did not receive biologics? In this analysis, patients served as their own controls over time.
Using a fixed effects mixed model, including previously significant covariates, we investigated the mean withinsubject improvement in HS activity for periods with vs.
without biologic therapy. The biologic 9 time interaction investigates whether this effect is stable across the followup period.
4 Did the effect of biologics differ in the patients who did vs.
did not receive HS surgery? To investigate whether the effect of biologic therapy depended on whether the patient also received surgery for HS, we examined the timevarying biologic exposure by surgery (ever) interaction in a random effects mixed model adjusted for baseline covariates. In this analysis, a significant three-way interaction indicated that there was a difference in HSS slope over time for those who ever vs. never received biologics, which varied as a function of receiving HS surgery. In addition, we tested whether the treatment group 9 time interaction was significant comparing patients who received biologic therapy and HS surgery with those who received biologics only.
5 In patients who did receive HS surgery, was the effect of biologics dependent on timing after surgery? Using a random effects mixed model adjusted for baseline covariates, we investigated only subjects who ever received surgery, and time from surgery was included as a predictor.
Time-to-event analysis for AN75
In order to account for differences in time at risk between the treatment groups, we also used time-to-event analysis for the first time point at which the patient's AN count dropped 75% from baseline (AN75). Patients who did not reach the endpoint were censored at their last visit. Kaplan-Meier analysis was used to compare patients in four groups: no surgery with no biologics, surgery only, biologics only, surgery with biologics.
Cox proportional hazard models were tested using the same four treatment groups, adjusting for any covariates that were significant in the mixed models. 
Results
Baseline demographics
There were 68 patients with HS included in this analysis. Mean (AE SD) age was 40 (AE14) years; 66% were female and 72%
were African American (Table 1) . Mean disease duration was 10 (AE12) years. The majority of patients had active disease, with baseline Hurley stage III seen in 63% of the patients. At baseline the overall mean HSS score was 61 (AE46). However, patients who had ever received biologics had higher baseline HSS and AN count than those who never received biologics.
Patients who ever vs. never received either biologics or HS surgery were more likely to also receive opioids (P = 0.04 for biologics and P < 0.0001 for surgery; Table 1 ).
Overall disease activity scores declined during follow-up Across all patients in the study, mean HSS scores, AN count, and Hurley stage declined over time (Fig. 1) . The decline from baseline in HSS was significant starting in quarter 2 (P < 0.0001), and the mean AN count drop was significant by quarter 1 (P = 0.007).
Ever receiving biologics was associated with sharper decline in HS activity than never receiving biologics
The HSS decline from baseline was larger in patients who received biologics than in those who never received biologics (P = 0.06 at Q2, 0.07 at Q3, 0.04 at Q4, 0.07 at year 2, and 0.01 at year 3; Fig. 2) . Similarly, the decline in AN count was sharper in patients who ever vs. never received biologics (P = 0.002). This remained significant after adjusting for baseline disease activity. Compared with those who never received biologics, patients who received biologics demonstrated greater reduction in HSS from baseline to Q2 (P = 0.047), Q3 (P = 0.07), Q4 (P = 0.03), Yr 2 (P = 0.05),
and Yr 3+ (P = 0.008). This was also true for AN count (biologicever 9 time period interaction, P = 0.0012) and Hurley stage (biologic-ever 9 time period interaction P < 0.0001). When other treatments (surgery-ever and opioids-ever) were added to the mixed model for biologics-ever by HSS (still controlling for baseline Shanmugam et al. Surgery with adjunctive biologic therapy for HS Reportdisease activity), the biologics-ever 9 time interaction remained significant (P = 0.03). Compared with patients who never received biologics, those who ever received biologics had a faster decline in HSS from baseline at Q2 (P = 0.046), Q3 (P = 0.07), Q4 (P = 0.038), year 2 (P = 0.046), and year 3+ (P = 0.005). Similar differences were seen in the AN count and Hurley stage when adjusting for surgery-ever and opioids-ever (interaction P = 0.0009 and P < 0.0001, respectively).
Impact of biologic therapy does not vary based on time period during which they are received
In the mixed model using biologics-ever as a time-varying predictor, after adjusting for baseline HSS and surgery-ever, we found that biologics-ever had a significant main effect (P = 0.0001) with a parameter estimate indicating that having received biologics was associated with a reduction in 35 points (95% confidence interval 13-57) in HSS score. The time-varying biologics 9 time interaction was not significant (P = 0.18), indicating that the effect of biologics did not vary depending on the time period during which they were received. Similar differences were seen in the AN count data; when biologics-ever was used as a time- The effect of biologics was greater in patients who did vs. did not receive HS surgery
We examined the interaction of time-varying biologic treatment and surgery-ever on HSS in order to determine whether the effect of biologics differed in patients who ever vs. never received surgery after adjusting for baseline HSS. This interaction was significant (P = 0.013). In patients who never had surgery, the HSS score dropped on average only 2 points in time periods with vs.
without biologics (mean HSS 45 [95% CI 36-54] vs. 43 [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] ).
In contrast in patients who ever had surgery, the HSS score dropped 27 points on average in time periods with vs. without biologics (42 vs. 15 ). Using the static biologic-ever predictor, comparing those who ever received biologics without surgery and those who received both biologics with surgery, the difference was significant (P = 0.003). Those who received biologics with surgery exhibited faster decline in HSS scores than those who received biologics without surgery (Fig. 3) .
The effect of biologics on AN count varied significantly, depending on whether the patient ever had HS surgery (interaction P = 0.033). In patients with HS surgery, time periods with biologics present were associated with a reduction in 0. and 3+ (Fig. 3b) . The effect of ever having biologics on Hurley stage over time similarly varied significantly depending on whether the patient ever had HS surgery (P < 0.0001).
Timing of biologics after surgery did not alter efficacy Combination therapy with surgery and biologic treatment was associated with a higher probability of achieving AN75
The log-rank chi-square was significant for time to 75% reduc- The effect of ever having biologics on the slope of HSS score over time varied significantly, depending on whether the patient ever had surgery (P-value for biologic 9 period 9 surgery interaction <0.0001, after adjusting for baseline HSS in mixed model regression). Just comparing those who ever received biologics without ever receiving surgery (BIOL-SURG) vs. those who received both, the difference was significant (P = 0.003): those who received both declined faster than those who received biologics only. (b) Mean active nodule (AN) count by time period, stratified by treatment combination. The effect of ever having biologics varied significantly, depending on whether or not the patient ever had surgery (biologic-ever 9 time period 9 surgery-ever interaction P < .0001). Patients with biologics only had a rebound in AN count in Yr2 and Yr3+, while those who also had surgery continued to show decline in AN count in Yr2 and Yr3+
Discussion
One of the roadblocks limiting HS research to date is that clinical trials of immunosuppressive agents in HS typically exclude surgical patients and tend to study patients with milder disease (of the 633 patients in the PIONEER I and II studies, approximately 70% had Hurley stage I and II disease, and patients undergoing surgery or requiring opioids for HS were excluded).
Another limitation of prior clinical trials in HS is that they study a predominantly Caucasian population (with only 18.8% of the population studied in the original adalimumab study being African American and only 14.4% of the PIONEER I and II study populations being African American). This lack of a diverse study population limits the generalizability of study findings to the US population. One of the major advantages to the WE-HEAL HS cohort is its longitudinal observational study design.
This allows investigation of the relationship between surgical intervention, opioid exposures, and pain in a cohort of diverse HS patients that is more representative of the population affected in the United States (72% African American). Furthermore, the study design allows for investigation of the complex interplay of time-varying factors such as opioid exposures, smoking, and pain, which play a crucial role in this disease.
The analysis presented has allowed investigation of critically important clinical outcome questions in the management of HS that are challenging to address in randomized clinical trials.
Specifically, one of the most important clinical questions in HS management is whether surgery alone, or in combination with biologic therapy, is the best management for HS and how best to time biologic therapy relative to surgical interventions. [12] [13] [14] In this study, we were able to demonstrate that patients who received biologic therapy had a more rapid decline in disease activity than those who never received biologics, and this held true after both adjusting for baseline disease activity and for other therapies including surgeries and opioid exposures. Biologic therapies were significantly associated with reduced disease activity scores regardless of the time period during which they were received. However, the effect of biologic therapies was greatest in patients who also underwent surgical intervention for their HS. The timing of biologic therapy relative to surgery did not seem to impact disease activity. Using time to event analysis, we were further able to demonstrate that patients who underwent surgical and biologic therapy had a higher probability of achieving a 75% reduction in AN count than those who received surgery or biologic therapy alone or neither.
The WE-HEAL HS observational cohort provides a unique resource for studying HS in the US population. The high prevalence and disease burden of HS in the African American population in the US means that it is crucially important to develop mechanisms to investigate therapies for this disease, but this population can be challenging to recruit to clinical trials. 38 The observational WE-HEAL study design has proven to be effective for investigating a diverse population of HS patients and is ideally suited for answering critically important questions in the management of this debilitating disease. While a major limitation of the study to date is the relatively small cohort size, recruitment to the WE-HEAL study is ongoing, and follow-up analysis is planned.
Conclusion
This longitudinal observational study of a diverse US population of HS patients demonstrates that both biologic therapies and HS surgical interventions are associated with improved disease activity scores but that the effect of biologic therapies was greatest when used as an adjunct to HS surgery.
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